carmustine has been researched along with Brain Damage, Chronic in 1 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández-Hidalgo, OA | 1 |
| Vanaclocha, V | 1 |
| Vieitez, JM | 1 |
| Aristu, JJ | 1 |
| Rebollo, J | 1 |
| Gúrpide, A | 1 |
| Aramendía, JM | 1 |
| Moreno-Palanques, R | 1 |
| Martín-Algarra, S | 1 |
| Subirá, ML | 1 |
| Brugarolas, A | 1 |
1 trial available for carmustine and Brain Damage, Chronic
| Article | Year |
|---|---|
High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Damage, Chronic; Brain Neoplasms; | 1996 |